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Abstract
Background: Infection of mice with the Armstrong strain of lymphocytic choriomeningitis virus
(LCMVARM) leads to a robust immune response and efficient viral clearance. This is in contrast to
infection with the variant strain LCMVClone13, which causes functional inactivation of effector T cells
and viral persistence. The mechanism by which LCMVClone13 suppresses the antiviral immune
response and persists in its host is unknown.
Results: Here we demonstrate that infection with LCMVClone13, but not with LCMVARM, resulted
in a steady increase in the serum levels of the immuno-inhibitory cytokine, IL-10. Blockade of IL-10
using neutralizing monoclonal antibody injections in LCMVClone13-infected mice led to dramatically
enhanced effector T cell responses at 8 days post-infection. Even though IL-10 blockade resulted
in decreased viral titers, the generation and maintenance of memory T cells was still compromised.
The functional inactivation of CD8+ T cells in IL-10-blocked, chronically infected mice 30 days post-
infection was incomplete as potent CTL (cytotoxic T lymphocytes) could be generated by in vitro
re-stimulation. IL-10 knockout mice showed a similar pattern of antiviral CD8 T cell responses:
early antiviral T cells were dramatically increased and viral levels were decreased; however, CD8
T cells in IL-10 knockout mice were also eventually anergized and these mice became persistently
infected.
Conclusion: Our data suggest that IL-10 plays an early role in LCMVClone13-induced tolerance,
although other factors collaborate with IL-10 to induce virus-specific tolerance.
Background
The immune system is versatile in its ability to respond
specifically to a wide variety of infectious agents. Specific
CD4 and CD8 T cell responses combined with robust
antibody responses clear invading viruses. While the host
efficiently clears most viruses, some have evolved strate-
gies to evade the immune system and establish persistent
infections. Viral persistence has been linked to a variety of
factors, including cell tropism, quantity and duration of
antigen persistence and several molecular viral immune
evasion strategies [1-8]. The end result is the incapacita-
tion of the immune response and the development of T
cell anergy or tolerance [3,9-12].
Cytokines control many aspects of the immune response,
and they affect the balance between the development of
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immunity and tolerance [9,13]. A robust Th1 response is
necessary for the resolution of infection and development
of immunity for the majority of viral infections. Inter-
leukin 10 (IL-10), a potent anti-inflammatory cytokine,
has been shown to dampen Th1 responses [14,15]. Sev-
eral groups have shown increased IL-10 levels during a
variety of persistent bacterial and parasitic infections,
including Candida albicans, Trypanosoma cruzi, and
Leishmania major [16-19]. Additionally, viral IL-10
homologues have been identified in the human viruses
Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV)
that have the ability to persistently infect their hosts, fur-
thering speculation that IL-10 plays a role in sabotaging
the adaptive immune response [20-22]. Despite the
mounting evidence in other systems, a role for host-pro-
duced IL-10 during chronic viral infections has not been
carefully studied until recently [23,24].
LCMVARM, a natural mouse pathogen, is a prototypic virus
infection model for studying effector and memory T cell
formation. Infected mice clear LCMVARM within 8 days,
and large numbers of memory CD8+ T cells that confer
life-long protective immunity persist in the host. In con-
trast, infection with LCMVClone13, a two amino acid
mutant of LCMVARM, leads to persistent viral infection and
T cell anergy: anergic CD8 T cells neither kill virus-infected
targets nor produce IFN-γ upon peptide stimulation [10].
The current study was undertaken to ascertain if IL-10
plays a role in establishing viral persistence by inducing T
cell anergy in LCMVClone13-infected mice. Here we show
increased levels of serum IL-10 in mice infected with
LCMVClone13, but not LCMVARM. Blocking IL-10 with a
neutralizing monoclonal antibody led to partial restora-
tion of T cell function and lowered viral titers if the anti-
body was administered during T cell priming. The critical
window for IL-10 in establishing anergy is early during the
immune response, as blockade of IL-10 after viral persist-
ence is established had no effect. However, the necessity
of IL-10 in establishing T cell anergy is not complete in
that LCMVClone13 established a persistent infection in IL-
10 deficient mice, despite a robust early CD8 T cell
response. This report clearly links persistent LCMV infec-
tion of mice, and the ensuing T cell anergy, to host-pro-
duced IL-10.
Results
Increased IL-10 expression following infection with 
LCMVClone13 but not LCMVARM
Increased levels of inhibitory cytokines such as Inter-
leukin 10 (IL-10) have been demonstrated during persist-
ent viral infections in humans [25,26]. Infection of mice
with LCMVClone13 induces anergy in CD4 and CD8 T cells,
whereas infection with LCMVARM leads to robust immu-
nity [10,27]. We were interested to see if persistent LCMV
infection led to increased levels of serum IL-10. We
infected cohorts of mice with either LCMVARM  or
LCMVClone13, collected their sera at various time points
post-infection (p.i.) and measured the IL-10 levels by
ELISA (Figure 1a). Other than an early spike of IL-10
detectable on day 2 post-infection, LCMVARM-infected
mice had low levels of IL-10 in their serum. IL-10 levels in
LCMVARM-infected mice increased slightly above naïve
mice as immune memory developed beyond day 20. In
contrast, LCMVClone13-infected mice accumulated IL-10 in
their serum. Beyond day 2 post-infection, LCMVClone13-
infected mice had significantly higher levels of serum IL-
10 compared to acutely infected mice, and the levels
increased with time. The steady increase in serum IL-10
was concomitant with the functional inactivation, i.e. loss
of cytolytic activity and IFN-γ production, in CD8 T cells
([28] and Figure 3). These data correlate the T cell anergy
observed in persistently LCMV infected mice with an
increase in serum IL-10.
Serum IL-10 levels in LCMV infected mice Figure 1
Serum IL-10 levels in LCMV infected mice. a) Sera 
from naïve (dashed line) or mice infected with LCMVARM 
(squares) or LCMVClone13 (circles) were assayed for IL-10 by 
ELISA at the indicated time points. The limit of detection of 
IL-10 by ELISA was 4 pg/ml. Serum IL-10 levels in naïve mice 
were at or below the limit of detection. Each time point rep-
resents 3–10 mice. b) IL-10 receptor expression was meas-
ured on CD8+ T cells in naïve mice and days 8 and 30 post 
infection by LCMVARM and LCMVClone13. The light line is 
staining by the isotype control and the bold line is IL-10R 
expression on gated CD8+ T lymphocytes. c) IL-10R expres-
sion on virus-specific CD8 T cells is upregulated in the con-
texts of acute and viral infection. Mice were infected with 
LCMVARM (bold red line) or LCMVClone13 (dashed blue line) 
and IL-10R expression was assessed eight days post-infection. 
Lymphocytes were gated on CD8 and DbGP33 tetramers. 
The solid histogram is the expression of IL-10R on naïve P14 
CD8+ lymphocytes.BMC Immunology 2007, 8:8 http://www.biomedcentral.com/1471-2172/8/8
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CD8 T cells are critical for controlling chronic LCMV
infection [27]. In order for IL-10 to directly effect CD8 T
cells, they must express the IL-10 receptor. We confirmed
IL-10R expression on CD8 T cells during the course of
acute and chronic infections. In our hands, IL-10R is uni-
versally high at day 8 post-infection for both acute (LCM-
VARM) and chronic (LCMVClone13) infections. By day 30,
IL-10R expression has decreased on a subset of memory
CD8 T cells in acutely infected mice. Persistently infected
mice, however, lose IL-10R expression on the majority of
CD8 T cells, consistent with the deletion of the majority
of anti-viral CD8 T cells. We next assessed IL-10R expres-
sion directly on LCMV-specific CD8 T cells. We looked at
splenic GP33-specific CD8 T cells eight days post-infec-
tion, a time during which chronically infected mice con-
tain virus-specific T cells with slightly impaired effector
functions. GP33-specific CD8 T cells in both acutely and
chronically infected mice had higher IL-10R expression
when compared to naïve CD8 T cells. These data are con-
sistent with the model that IL-10 directly affects CD8 T
cells.
IL-10 blockade enhances IFN-γ production in persistently 
infected mice 8 days post-infection
We next wanted to determine if neutralizing IL-10 would
have an effect on the developing T cell response during a
chronic viral infection. We injected LCMVClone13-infected
mice with anti-IL-10 antibodies or normal rat IgG on days
0, 2, and 4 after infection. Eight days following infection,
CD8+ and CD4+ T cell responses were measured by pep-
tide-induced IFN-γ production and cytolytic killing of
peptide-pulsed target cells. LCMVClone13-infected animals
exhibited depressed CD8 T cell responses: the frequency
of cells responding to the immunodominant epitopes
NP396 and GP33 was reduced by 60–80% when com-
pared to LCMVARM-infected mice (Figure 2a). In contrast,
mice that received IL-10 blockade exhibited enhanced T
cell responses. The frequencies of NP396 and GP33
tetramer+ CD8 T cells were comparable to those observed
in LCMVARM-infected mice (data not shown). The amount
of IFN-γ production per cell, as measured by mean fluo-
rescence intensity (MFI) was higher in anti-IL-10 treated
mice than in LCMVClone13-infected, rat IgG treated con-
trols for both LCMV peptides, GP33 (350 ± 12.5 vs. 248.5
± 39.5 for anti-IL-10 treated vs. rat IgG treated) and
NP396 (204 ± 30 vs. 116.7 ± 12.2).
LCMVClone13-infected mice receiving anti-IL-10 therapy
exhibited a level of IFN-γ production that was indistin-
guishable from LCMVARM-infected mice (Figure 2a). Mice
receiving anti-IL-10 therapy had larger spleens and signif-
icantly more (5–7 fold) virus-specific CD8+  T lym-
phocytes, relative to untreated LCMVClone13-infected
control mice (Figure 2b).
Neutralizing IL-10 leads to enhanced T cell responses in  LCMVClone13-infected mice at day 8 post-infection Figure 2
Neutralizing IL-10 leads to enhanced T cell responses 
in LCMVClone13-infected mice at day 8 post-infec-
tion. a) Splenocytes from mice infected with LCMVARM (left 
column), LCMVClone13 (middle column), or LCMVClone13 and 
given anti-IL-10 antibodies (right column), were stimulated 
with LCMV class I peptides, GP33-41 or NP396-404, class II 
peptides, GP61-80 and NP309-324 and control ovalbumin 
(OVA) peptides and IFNγ production was measured by intra 
cellular cytokine staining. Numbers below representative 
plots indicate the frequency CD69+ IFNγ+ T cells. The cells 
gated (CD4 or CD8) are indicated in parentheses. Plots are 
representative of 5 mice in each group. b) The total number 
LCMV-specific IFN-γ+ splenic CD8 and CD4 T cells from the 
mice infected with LCMVClone13, or LCMVClone13 treated with 
anti IL-10 are shown in open and hatched bars, respectively. 
Data from acutely-infected LCMVARM mice are shown in the 
filled bars for comparison. The LCMV peptides used for stim-
ulation and the cell gating strategy are indicated below the 
graph. These data are representative from two independent 
experiments; the average of 5 mice per group is graphed. c) 
Anti-IL-10 treated, LCMVClone13-infected mice exhibit potent 
CTL responses. Splenocytes from uninfected or mice were 
infected with LCMVARM, LCMVClone13, LCMVClone13 plus anti-
IL-10 were tested for CTL activity against target cells pulsed 
with LCMV NP396-404, GP33-41, or control OVA peptides 
(not shown), 8 days p.i. using a standard 51Cr release assay 
[33]. d) LCMVClone13-infected mice receiving anti-IL-10 mAbs 
have lower viremia. Day 8 p.i. sera from LCMVClone13 infected 
mice with (filled circles) or without (open circles) anti-IL-10 
treatment were tested for infectious virus by plaque assay 
[35]). e) Anti-IL-10 treatment did not lead to enhanced 
humoral responses at day 8 post-infection. Sera were col-
lected from mice infected with LCMVClone13 with and without 
anti-IL-10 treatment at 8 days post-infection and LCMV-spe-
cific antibodies were assessed by ELISA. There was no statis-
tical difference (p = 0.2) in the serum anti-LCMV antibody 
levels between these two groups.BMC Immunology 2007, 8:8 http://www.biomedcentral.com/1471-2172/8/8
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CD4 T cells are essential for maintaining antiviral CD8 T
cells [27,29]. Therefore, we monitored the effect of anti-
IL-10 treatment on rescuing virus-specific CD4 T cell func-
tion by testing their ability to produce IFN-γ upon stimu-
lation with the LCMV MHC class II peptides GP61 and
NP309. Anti-IL-10-treated mice exhibited higher levels of
IFN-γ production by CD4+ T cells at 8 days p.i. (5.5% ± 1.2
vs. 1.5% ± 0.7 for anti-IL-10 treated vs. untreated
LCMVClone13-infected mice, p = 0.033, Figure 2a). The
absolute numbers of LCMV-specific CD4 T cells were also
higher in the anti-IL-10 treated LCMVClone13-infected
group as compared to LCMVClone13-infected mice that did
not receive anti-IL-10 treatment (Figure 2b). Thus, neu-
tralizing IL-10 during the time that T cell priming occurs
drastically enhanced peak antigen-specific CD4 and CD8
T cell responses, both in absolute numbers and in func-
tion as measured by IFN-γ production.
IL-10 blockade restores CTL activity and lowers viral load
Cytolytic killing is a hallmark of activated antigen-specific
CD8 T cells, and it is one of the first properties to be lost
in persistently infected mice [10,27]. We wanted to know
if IL-10 blockade restored the cytolytic activity of CD8 T
cells. We measured the cytolytic activity of CD8 T cells by
51Cr release assay using target cells pulsed with the immu-
nodominant LCMV peptides NP396 and GP33 (Figure
2c). Killing of target cells was dramatically impaired in
LCMVClone13-infected mice at 8 days p.i., but neutralizing
IL-10 in vivo restored cytotoxic activity nearly to levels
observed in LCMVARM-infected mice (Figure 2c). We then
tested the mice to determine whether enhanced T cell
responses induced by neutralizing IL-10 led to a reduction
in viral load. Despite the improved CTL and cytokine
responses in mice receiving IL-10 blockade (Figure 2a–c),
they still had infectious virus (Figure 2d). However, the
level of viremia was significantly reduced (> 1 log) in mice
receiving IL-10 blockade (1.6 × 105 ± 3.9 × 104 pfu/ml, n
= 5, for LCMVClone13 infections vs. 2.3 × 104 ± 6.7 × 103
pfu/ml, n = 5, for LCMVClone13  plus anti-IL-10, p =
0.0076). The lowered viral titers observed at day 8 p.i.
could be due to enhanced cytolytic T cell activity or due to
an enhanced antibody response to LCMV in anti-IL-10
treated mice, or a collaboration of the two effects. To dis-
tinguish between these two possibilities we compared the
anti-LCMV antibody responses at day 8 post-infection in
groups of LCMVClone13-infected mice with or without anti-
IL-10 treatment. Anti-IL-10 blockade did not result in
enhanced virus-specific humoral responses (Figure 2e).
LCMV-specific IgG levels in the IL-10-blocked, persist-
ently infected mice were not significantly different than
untreated controls at day 8 post infection (p = 0.2). The
data suggest that enhanced cytotoxic CD8 T cell responses
and not humoral responses are responsible for the low-
ered viral titers observed in the anti-IL-10 treated mice
early in the response. These data further support the con-
cept that host-produced IL-10 directly impacts LCMV-spe-
cific CD8 T cells early during the immune response.
Despite the initial enhanced response, mice receiving a 
short course of IL-10 blockade contain a mixture of 
functional and anergized CD8 T cells, and exhibit a low-
level persistent viremia
In LCMVClone13-infected mice receiving IL-10 blockade,
IFN-γ production and cytolytic killing by CD8 T cells were
intact, and CD4 T cell responses were also enhanced at
day 8 p.i. (Figure 2a). It was essential to determine if this
potent antiviral immune response could develop into
immune memory and resolve the viral infection. We ana-
lyzed CD8 T cells from immune LCMVClone13-infected
mice (day 30) with and without IL-10 blockade for LCMV-
specific MHC/tetramer binding (Fig. 3a) and IFN-γ pro-
duction (Fig. 3b). In untreated LCMVClone13-infected mice,
we observed large numbers of GP33 tetramer+ CD8 T cells
that failed to produce IFN-γ, a characteristic phenotype of
anergized virus-specific T cells [10]. CD8 T cells specific
for the NP396 epitope were mostly deleted and the rare
NP396 tetramer binding cells that were present failed to
produce IFN-γ upon peptide stimulation. In contrast,
mice receiving IL-10 blockade had a small fraction of CD8
T cells that produced IFN-γ when stimulated with GP33
peptide (0.5% ± 0.2 vs. 0.1% ± 0.1%, Fig. 3b), indicating
that, at least on some level, functional CD8 T cells were
present in persistently infected mice that received IL-10
blockade. Persistently infected, anti-IL-10 treated mice
deleted NP396-specific CD8 T cells, similar to
LCMVClone13-infected, rat IgG-treated control mice. Taken
together, the tetramer and IFN-γ data for two immunodo-
minant epitopes suggest that the generation of virus-spe-
cific memory cells was impaired although some GP33-
specific CD8 T cells that retain IFN-γ production persisted
in mice that received IL-10 blockade (Figure 3b). We also
monitored CD4 T cell responsiveness at 30 days p.i. A
small population of GP61/NP309-specific CD4+ T cells
remained in IL-10 blocked mice, although the MFI of IFN-
γ production was low (Figure 3b).
Anti-IL-10 treated, LCMVClone13-infected mice remained
persistently infected at 30 days p.i. (Figure 3c). However,
viremia was approximately 1.5 logs lower in LCMVClone13-
infected mice that received anti-IL-10 therapy (2.4 × 103
± 6.6 × 102 pfu/ml, n = 5, for LCMVClone13 plus anti-IL-10
vs. 4.2 × 104 ± 1.1 × 104 pfu/ml, n = 5, for LCMVClone13).
IL-10 blockade in mice with established persistent 
infections did not result in enhanced T cell responsiveness 
or lowered viral titers
Blocking IL-10 early in the infection during T cell priming
(days 0–4) led to enhanced LCMV-specific T cell
responses and lower viral titers. We wanted to know if
blocking IL-10 was a useful strategy in lowering viral titersBMC Immunology 2007, 8:8 http://www.biomedcentral.com/1471-2172/8/8
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in mice with established persistent infections. We chose
mice that were persistently infected with LCMVClone13 (day
30 p.i.) and injected them with normal rat IgG or anti-IL-
10 antibodies on days 30, 32 and 34 post-infection. Two
weeks following anti-IL-10 treatment we assayed these
mice for CD4 and CD8 T cell function and measured
serum viral titers. IL-10 blockade after establishment of
viral persistence had no effect on LCMV-induced T cell tol-
erance. T cell anergy could not reversed (data not shown),
and there was no change in viremia (Figure 3d). T cells
from mice treated with anti-IL-10 late in the infection
were non-functional and indistinguishable from
untreated LCMVClone13-infected mice (data not shown).
These data suggest that there is an early critical window
during which IL-10 works to induce anergy in T cells.
Mice receiving early anti-IL-10 therapy exhibit CTL 
activity following in vitro re-stimulation
Next, we wanted to know if the anergy observed in anti-IL-
10 treated, LCMVClone13-infected mice was complete and
irreversible, or if the effector/memory T cells that
remained could expand and function. Splenocytes from
LCMVClone13-infected mice (day 30 p.i.) were stimulated
in vitro with GP33 peptide, in the presence of IL-2, for 5
days and their ability to kill target cells was determined by
51Cr release assay (Figure 4a). Re-stimulation in vitro
restored cytolytic activity of LCMVClone13-infected anti-IL-
10 treated mice; their CTL activity was comparable to
LCMVARM-immune mice. In contrast, GP33-specific CD8
T cells from LCMVClone13-infected, untreated mice were
refractory to peptide re-stimulation and failed to kill target
cells. These data clearly demonstrate that IL-10 blockade
early in the viral infection led to incomplete tolerization
of virus-specific CD8 T cells despite the fact that these
mice had low-level viremia.
Mice receiving anti IL-10 therapy have an enhanced 
antibody response against LCMV 30 days post-infection
We assessed the antiviral antibody titers 30 days p.i. in
LCMVClone13-infected mice with and without anti IL-10
treatment (Figure 4b). Interestingly, mice receiving IL-10
blockade had significantly greater levels of LCMV-specific
antibodies than mice that did not receive anti-IL-10 ther-
apy (O.D. 0.4201 ± 0.045, n = 8 vs. 0.1875 +/- 0.035, n =
6, p = 0.002). The level of antiviral IgG in LCMVARM
immune mice was much greater than the LCMVClone13-
infected mice that received anti-IL-10 blockade (1.151 ±
0.042, n = 10 versus 0.4201 ± 0.045, n = 8, p < 0.0001, not
shown). These data, combined with the low antiviral anti-
body levels seen 8 days p.i., show that the LCMV-specific
antibody response matured with time in the IL-10
blocked mice.
IL-10 knockout mice recapitulate the phenotype observed 
in anti-IL-10 antibody treated mice: early T cell 
enhancement followed by induction of anergy
The data presented so far clearly show that IL-10 blockade
led to enhanced early T cell responses but not the eradica-
tion of virus. One possibility is that the T cell anergy
observed at 30 days p.i. could be due to the inefficiency of
the antibody treatment. Continued blockade of IL-10
throughout the course of persistent LCMVClone13 infection
may result in complete viral clearance and the develop-
ment of T cell immunity. To decisively determine the
causal role of IL-10 in generating T cell anergy during per-
sistent viral infections, and to avoid the vagaries of multi-
ple injections of heterospecific neutralizing antibodies,
Early anti-IL-10 therapy improves virus control 30 days p.i Figure 3
Early anti-IL-10 therapy improves virus control 30 
days p.i. a) Spleen cells from naïve, LCMVARM, and 
LCMVClone13-infected mice with and without anti-IL-10 treat-
ment (day 30 p.i.) were stained with LCMV tetramers 
DbGP33 and DbNP396. The numbers shown are the fre-
quency of tetramer+ cells per CD8+ T cells. Plots are repre-
sentative of 5 mice. b) IFNγ production by CD8 T cells 30 
days p.i. Splenocytes were stimulated with LCMV MHC class 
I restricted peptides, GP33-41 or NP396-404 or class II pep-
tides GP61-80 and NP309-324 and then assayed for IFNγ 
production by ICCS. All plots are gated on CD8 T cells and 
the numbers indicate the frequency of CD69+ IFNγ+ cells. c) 
Anti-IL-10 treated mice exhibited lower viremia at 30 days p.i 
Sera from LCMVClone13-infected mice without (open circles) 
and with (filled circles) anti-IL-10 treatment were tittered for 
infectious virus by plaque assay. Naïve and LCMVARM immune 
mice were free of virus (not shown). d) Anti-IL-10 treatment 
in mice with established persistent infections does not lead 
to lowering of viral titers. Cohorts of mice infected 30 days 
earlier with LCMVClone13 were injected with anti IL-10 ther-
apy on days 30–34 p.i Their sera were collected two weeks 
later and assayed for infectious virus by plaque assay. The 
LCMV titers from untreated (open cirlces) and anti-IL-10 
treated (filled circles) mice are shown.BMC Immunology 2007, 8:8 http://www.biomedcentral.com/1471-2172/8/8
Page 6 of 9
(page number not for citation purposes)
we attempted to persistently infect IL-10 deficient mice.
We first tested the ability of IL-10-/- mice to clear acute
LCMVARM  infections. Cohorts of IL-10-/-  mice were
infected with 2 × 105 pfu of LCMVARM and their ability to
mount T cell responses and clear virus was assayed at 8
days post infection. IL-10-/- mice mounted robust CD8 T
cell responses (Figure 5a) and cleared LCMVARM (Figure
5b) as efficiently as wild type mice. We then infected IL-
10-/- mice with LCMVClone13 and examined their T cell
responses and ability to clear virus at days 8 and 30 p.i. IL-
10-/- mice exhibited exaggerated T cell responses at 8 days
p.i., while wild type mice exhibited virus-induced
immune suppression. Interestingly, heterozygous IL-10+/-
littermate controls exhibited T cell responses intermediate
between those of control IL-10+/+ and IL-10-/- mice (Figure
5c). However with time, IL-10-/- mice, as well as IL-10 het-
erozygotes, lost their virus-specific CD8+  T cells and
became persistently infected by day 30 p.i. (Figures 5c, d).
We also tracked the IFN-γ responses to three other LCMV
epitopes, including subdominant epitopes, and the pat-
terns were identical (data not shown); responses to all
epitopes tested were absent 30 days p.i. in IL-10-/- mice.
These data confirm and extend the observations made
using anti-IL-10 antibody treatment and clearly demon-
strate that IL-10 plays a direct and early role in generating
T cell tolerance; however, additional mechanisms are
operating to generate and/or maintain virus-induced
anergy.
Discussion
Early anti-IL-10 therapy resulted in an impressive
enhancement in the cellular immune response to
IL-10-/- efficiently clear LCMVARM but upon infection with  LCMVClone13 these mice exhibit an early enhanced T cell  response, followed by anergy and viral persistence Figure 5
IL-10-/- efficiently clear LCMVARM but upon infec-
tion with LCMVClone13 these mice exhibit an early 
enhanced T cell response, followed by anergy and 
viral persistence. a) IL-10-/- (open bars) or control wild 
type (WT) C57BL/6 (filled bars) mice were infected with 
LCMVARM and 8 days later the CD8 T cells were assayed for 
their ability to produce IFN-γ upon stimulation with LCMV 
peptides, GP33 and NP396. The frequencies ( ± standard 
deviation) of IFN-g+ CD8+ T cells for the two groups of mice 
are shown; there was no significant difference between the 
groups. b) IL-10-/- mice clear LCMVARM as efficiently as 
C57BL/6 mice. Groups of mice were infected with 2 × 105 
pfu LCMVARM and eight days post infection, the sera from IL-
10-/- (open circles) and WT, C57BL/6 (filled circles) mice 
were assayed for infectious virus by plaque assay. c) Cohorts 
of C57BL/6 (IL-10+/+), IL-10+/- and IL-10-/- mice were infected 
with LCMVClone13 and 8 or 30 days later, the ability of CD8 T 
cells to produce IFN-g upon stimulation with LCMV peptides, 
GP33 (filled bars) and NP396 (open bars) were assayed by 
intracellular cytokine staining. The absolute numbers of 
splenic IFN-γ+ CD8+ T cells ( ± SD) for the three groups are 
plotted. Robust CD8 T cells responses were observed in IL-
10-/- mice. For each of the peptide stimulation at day 8, the 
numbers of IFN-γ+ CD8+ T cells in IL-10-/- were statistically 
significant than those in IL-10+/- (p < 0.01) and IL-10+/+ (p < 
0.001) mice. The numbers of IFN-γ+ CD8 T cells in IL-10+/- 
and wild type, IL-10+/+ mice were not statistically significant. 
d) Both IL-10+/+ and IL-10-/- mice remained persistently 
infected, 30 days after infection with LCMVClone13. Sera from 
infected, IL-10-/- (open circles) and IL-10+/+ (filled circles) 
were assayed for virus by plaque assay. The difference in the 
viral titers between the two groups was not statistically sig-
nificant. Each dot represents an individual mouse.
LCMVClone13 infection induced anergy induced in CD8 T  cells is reversed by anti-IL-10 treatment Figure 4
LCMVClone13 infection induced anergy induced in 
CD8 T cells is reversed by anti-IL-10 treatment. a) 
Splenocytes from LCMVARM immune (dashed line), 
LCMVClone13-infected with (closed square) or without (open 
square) anti-IL-10 (day 30 p.i.), were stimulated in vitro for 5 
days with LCMV GP33 peptide and IL-2, and their capacity to 
lyse LCMV GP33 peptide-pulsed targets was measured by 
51Cr release assay. The effector to target ratio was calculated 
based on CD8 frequency. There were 5–7 mice per group, 
each line represents one mouse. Background killing in 
unpulsed target cells was less than 10%. b) The amount of 
anti-LCMV IgG, 30 day p.i., in the sera of naïve (filled 
squares), LCMVClone13 infected with (filled triangles) and with-
out anti IL-10 treatment (filled circles) was measured by 
ELISA. The difference in anti-viral IgG between the 
LCMVClone13-infected mice receiving anti-IL-10 versus 
untreated is statistically significant (p = 0.002).BMC Immunology 2007, 8:8 http://www.biomedcentral.com/1471-2172/8/8
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LCMVClone13  at 8 days p.i. and the humoral immune
response 30 days p.i IL-10-blocked mice had significantly
higher IFN-γ production in CD8 and CD4 T cells, both in
frequency and magnitude. Cytolytic activity was also
enhanced in the anti-IL-10 treated mice. Thus, IL-10
blockade clearly bolstered the early immune response to
LCMV such that the immune response in LCMVClone13-
infected mice receiving anti-IL-10 was indistinguishable
from non-persisting LCMVARM acute infections at 8 days
p.i. However, neutralizing IL-10 did not completely block
virus-induced CD8 T cell inactivation. Thirty days p.i.,
LCMVClone13-infected mice receiving anti-IL-10 contained
GP33-specific CD8 T cells, the majority of which failed to
produce IFN-γ, or were 'exhausted', although, some did
retain the ability to produce IFN-γ upon peptide re-stimu-
lation. Interestingly, the functional deficit observed in
CD8 T cells in anti-IL-10 treated mice was not complete;
cytolytic killing could be rescued by peptide re-stimula-
tion in vitro in the presence of IL-2. While early anti-IL-10
treatment did not prevent viral persistence, these mice
exhibited significantly lower viremia compared to rat IgG-
treated control mice.
Although IL-10 blocked mice became chronically
infected, we were able to rescue cytolytic killing following
in vitro stimulation in the presence of IL-2 (Figure 4a).
However, in our in vitro studies it was impossible to deter-
mine if we rescued cytolytic killing in all or only a fraction
of GP33-specific CD8 T cells. Indirect evidence, presented
in Fig. 3a &3b, shows that whereas nearly all virus-specific
memory cells in acutely infected mice produce IFN-γ
when stimulated, only a fraction of virus-specific CD8 T
cells in chronically-infected IL-10-blocked mice were able
to make IFN-γ. Although IFN-γ production and IL-2 recep-
tivity are not clearly or directly linked, these data suggest
that we were able to rescue cytolytic killing in only a frac-
tion of virus-specific CD8 T cells in the IL-10 blocked
mice. Indeed, others have shown that the majority of
memory cells proliferate in response to IL-2 [30]. That
same group showed that anergized cells did expand in
response to IL-2 in the context of persisting antigen,
although it was unclear what proportion of virus-specific
CD8 T cells were proliferating.
Our data support a scenario in which neutralizing IL-10
enhances the initial CD4 T cells, which in turn leads to an
increased magnitude and maintenance of virus-specific
CD8 T cells early in the response, possibly by sustained IL-
2 production. Additionally, neutralizing IL-10 may have
direct effect on CD8 T cells, as indicated by the increased
IL-10R expression on virus-specific CD8 T cells (Fig. 1b).
Virus-specific CD8 T cells with enhanced cytolytic activity
keep the initial virus levels low. At this early phase, anti-
body levels may play a minimal role. Thirty days later,
when the majority of CD8 T cells are rendered non-func-
tional by the persistent virus, viremia is kept low by virus-
specific antibodies. It is clear from our data that IL-10
plays a critical role in inducing T cell anergy during per-
sistent LCMVClone13 infections, and that its effect is most
potent early in the immune response. Neutralizing IL-10
does not completely block immune tolerance or prevent
viral persistence, suggesting that other factors are playing
a significant role.
A potential criticism of the antibody-mediated IL-10 neu-
tralization studies is that IL-10 was not blocked through-
out the course of the virus-infection. Perhaps continued
IL-10 blockade would have led to eventual clearance of
virus. Our experiments in IL-10-/- mice unequivocally set-
tle this issue. IL-10 deficiency resulted in improved early
adaptive immune responses similar to the antibody-medi-
ated IL-10 neutralization studies. However, with time,
CD8 T cells from IL-10-/- mice became non-functional and
the mice were persistently infected. Thus, whether by anti-
body- mediated neutralization or by genetic disruption,
the removal of IL-10 had a drastic stimulatory effect on
the early antiviral CD8+ and CD4+ T cell responses but its
effects were minimal later in the response. This finding
leads us to conclude that IL-10 exerts its strongest effect
early during infection and other factors operate later dur-
ing infection to bring about virus-induced T cell tolerance,
such as TGF-β or PD-1 expression on CD8 T cells [31].
Inducing IL-10 production in the host or encoding homo-
logues of IL-10 is a common strategy utilized by various
pathogens to induce anergy in the host [15]. Here we
show that LCMVClone13 also uses this strategy to subvert
the host immune response. LCMVClone13 differs from the
Armstrong strain by two amino acids, one in the polymer-
ase and the other in the glycoprotein (GP). The mutation
in the polymerase enables the virus to replicate at a higher
rate than LCMVARM [27,32]. Interestingly, the mutation in
GP alters its tropism. Oldstone and colleagues have ele-
gantly shown that LCMVClone13 infects DEC205+ CD11c+
dendritic cells while LCMVARM fails to do so [1,2]. We
speculate that infection of DCs with LCMVClone13 leads to
IL-10 production by these cells directly or, alternatively,
infected DCs could induce regulatory T cells that in turn
would secrete IL-10. Our experiments clearly show that
while IL-10 is important for virus-induced tolerance
induction, there must be other factor(s) that are involved
as well. Whether these are IL-10 family members [15]
such as IL-19, IL-20, IL-22, AK155 and mda-7 or immuno-
modulatory cytokines such as TGF-β, remains to be inves-
tigated. Clearly, ligation of PD-1 on CD8 T cells by PD-L1
and/or PD-L2 can have a suppressive effect, but the kinet-
ics of co-stimulation and co-inhibition during chronic
LCMVClone13 infections have not been clearly defined.BMC Immunology 2007, 8:8 http://www.biomedcentral.com/1471-2172/8/8
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During the preparation of this manuscript, it has come to
the attention of the authors that other laboratories have
performed similar experiments with differing results
([24,23]). Although the authors used a blocking antibody
to IL-10R that may have been more efficacious then neu-
tralizing IL-10 directly with different kinetics of adminis-
tration, Brooks et al. also performed LCMVClone13
infections in IL-10 knockout mice and observed viral
clearance. The route and amount of virus, as well as the
genetic background of the IL-10-/- mice, were reportedly
identical to those used in our studies; as such, we have no
explanation for the difference in outcome.
Conclusion
The data presented in this paper show that IL-10 assists in
generating T cell anergy to a viral infection, and that its
role is perhaps most important during T cell priming.
Serum IL-10 levels increased during chronic LCMV infec-
tions, and neutralizing IL-10 with a monoclonal antibody
resulted in improved antiviral CD8 and CD4 T cell
responses, as well as antiviral B cell responses. In agree-
ment with our antibody studies, chronically infected IL-10
deficient mice displayed CD8 T cell responses that were
indistinguishable from IL-10-blocked mice: the early anti-
viral response was significantly enhanced. However, both
IL-10-blocked mice and IL-10 deficient mice were eventu-
ally tolerized to LCMV, evidenced by the presence of aner-
gic virus-specific CD8 T cells and persisting virus. These
data suggest that although host-produced IL-10 plays a
role in generating virus-specific tolerance early during
infection, other factors collaborate to completely tolerize
CD8 T cells.
Methods
Mice and viral infections
All animal experiments were conducted with IACUC
approval. C57BL/6J mice and P14 (B6;D2-Tg(TcrL-
CMV)327Sdz/JDvsJ) mice maintained on a B6 back-
ground were purchased from the Jackson Laboratory (Bar
Harbor, ME) and maintained under specific-pathogen-
free conditions in the rodent vivarium at the Emory Vac-
cine Center. IL-10 knockout mice were a kind gift from Dr.
Elizabeth Bonney (University of Vermont). Viruses, LCM-
VARM and LCMVClone13were kind gifts from Dr. R. Ahmed
(Emory University) and Dr. A. Zajac (University of Ala-
bama, Birmingham). Non-persistent and persistent infec-
tions were generated by injecting mice with 2 × 105 pfu
LCMVARM intraperitoneally or 2 × 106 pfu LCMVClone13
intravenously, respectively. Cohorts of LCMVClone13-
infected mice received normal rat IgG (Sigma) or anti-IL-
10 (BD Biosciences) injections either early (200 µg on day
0, 100 µg on days 2 and 4), or late (100 µg each on days
30, 32, and 34).
Flow cytometry
Flow cytometry was performed on spleen cell suspensions
as described [33]. Intracellular cytokine staining (ICCS)
was done on splenocytes that were stimulated with
LCMV-specific MHC class I peptides, NP396-404 and
GP33-41, or MHC class II peptides, NP309-324 and
GP61-80 [34], or ovalbumin SIINFEKL (OVA). Anti-
CD210 (IL-10R, BD Biosciences) staining was performed
intracellularly on peptide stimulated splenocyte cultures.
IL-10 ELISA
Mouse sera were collected and ELISAs were performed
using the IL-10 Quantikine M kit (R & D Systems).
Viral load plaque assay
Serum LCMV titers in serum were determined by plaque
assay as described [33].
CTL assay
CTL assays were performed using a standard 51Cr release
assay using targets pulsed with LCMV NP396-404, GP33-
41, or OVA peptides as described [33]. Supernatants from
the 51Cr release assay were collected and transferred to
Wallac plates, air dried, and read in a Wallac MicroBeta
TriLux Liquid Scintillation Counter (Wallac, Turku, Fin-
land). For restimulation experiments, single cell suspen-
sions of spleens from LCMVARM immune mice (n = 2) or
LCMVClone13-infected mice with (n = 5, 200 µg anti-IL-10
given on day 0, 2, & 4) or without IL-10 blockade (n = 7)
were cultured for 5 days in the presence of 100 U/mL
recombinant human IL-2 (R&D Systems). Media was
refreshed either other day, no exogenous antigen or pep-
tide was added. After the stimulation, 5 × 105 cells were
plated with serial dilutions of 51Cr-labeled GP33 peptide-
pulsed MC57 g fibroblast targets. Aliquots of stimulated
cells were checked by flow cytometry in order to deter-
mine the proportion of CD8+ T cells in each sample and
the ratio of CD8 T cells : target cells was mathematically
adjusted. Percent specific killing was calculated as [(exper-
imental - spontaneous)/(max - spontaneous)] × 100.
Determination of serum anti-LCMV antibody titer
LCMV-specific serum antibody levels were measured by
ELISA as described [35]. Briefly, cell lysates from LCMV
infected BHK-21 cells were adsorbed on to Immunosorp
(Nunc) plates by overnight incubation at 4°C. Plates were
blocked with 4% milk in PBS and serum samples (1:50
dilution) were added and incubated 90 minutes. Follow-
ing incubation, the plates were washed extensively and
the amount of bound IgG was determined by using goat
anti-mouse IgG mAb conjugated to horseradish peroxi-
dase (Vector). Bound mouse IgG was visualized by addi-
tion of colorimetric peroxidase substrate from R&D
Systems.BMC Immunology 2007, 8:8 http://www.biomedcentral.com/1471-2172/8/8
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Statistical analyses
We used Student's t test analyses to compare the means of
different groups of mice. For statistical analysis of data
from the IL-10-/- mice, we used one-way ANOVA followed
by Bonferroni post test.
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